<DOC>
	<DOCNO>NCT01104675</DOCNO>
	<brief_summary>The purpose study determine whether oral ENMD-2076 effective treatment patient platinum resistant ovarian , fallopian , peritoneal cancer . Additional sit add .</brief_summary>
	<brief_title>Study Oral ENMD-2076 Administered Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Have histologically document diagnosis ovarian , fallopian peritoneal cancer platinum resistant . Have prestudy echocardiogram multigated acquisition ( MUGA ) scan actual leave ventricular ejection fraction great equal institution lower limit normal Greater equal 18 year age Have clinically acceptable laboratory screen result Have ECOG performance status 0 1 Able tolerate oral medication Have uncontrolled hypertension ( systolic blood pressure great 150mmHg diastolic blood pressure great 100mmHg ) ; require two antihypertensive medication control hypertension ( include ACE inhibitor , beta blocker , calcium channel blocker , diuretic ) Have chronic atrial fibrillation QTc interval correct heart rate great 470 msec Have active , acute , chronic clinically significant infection bleed Have persistent 2+ protein urinalysis history nephrotic syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>ovarian</keyword>
	<keyword>platinum resistant ovarian cancer</keyword>
</DOC>